Physician profile
Bradley R Corr
NPI 1255566964
$70,012.73
in general payments reported to CMS, 2019-2025
21 companies · $13K in 2025
The $13K reported for 2025 was more than what 92% of Gynecologic Oncology providers received nationally (typical 2025 total: $305).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,601 · 2020: $5,983 · 2021: $12K · 2022: $5,692 · 2023: $12K · 2024: $17K · 2025: $13K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $38K · Grant: $1,344 · Food and Beverage: $1,201 · Travel and Lodging: $819 · Education: $50.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $37,770.50 |
| Grant | $1,344.02 |
| Food and Beverage | $1,200.80 |
| Travel and Lodging | $818.74 |
| Education | $50.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $26,457.00 | 2020-2025 | Jemperli, Zejula |
| Astrazeneca Pharmaceuticals Lp | $9,063.40 | 2021-2024 | Lynparza |
| Merck Sharp & Dohme LLC | $8,795.00 | 2020-2023 | |
| Abbvie INC. | $6,698.75 | 2024-2025 | |
| Eisai INC. | $4,125.00 | 2023-2025 | |
| Tesaro, INC. | $3,274.49 | 2019 | |
| Gilead Sciences, INC. | $3,244.08 | 2023-2024 | |
| Novocure INC. | $2,198.26 | 2019-2020 | |
| Biontech Se | $2,160.00 | 2025 | |
| Daiichi Sankyo INC. | $1,938.00 | 2025 | |
| Immunogen, INC. | $1,305.02 | 2023-2024 | Elahere, Elahere |
| Foundation Medicine, INC. | $229.00 | 2022 | |
| Novocure Gmbh | $209.54 | 2022 | |
| Seagen INC. | $128.60 | 2022 | |
| Genentech USA, INC. | $126.78 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Clovis Oncology, INC. | $59.81 | 2019 |
5 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bradley Corr listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.